BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development centered at University Hospitals in Cleveland, Ohio, announced that it has expanded its strategic partnership with Biogen to include the ophthalmology therapeutic area, in addition to its existing neurology partnership. This discovery collaboration will leverage the strengths of both organizations to identify pioneering ophthalmic discoveries and advance them into medicines.

"We are very pleased to build on our strategic partnership with Biogen as they are committed to working collaboratively to advance products based on truly novel scientific insights," said Baiju R. Shah, chief executive officer of BioMotiv. "The expanded relationship enables us to integrate Biogen's strategic insights into the development of a pipeline of breakthrough ophthalmic innovations that have the potential for high patient impact."

With the additional investment by Biogen of $10 million and commitments by other investors, the total capitalization for BioMotiv has now reached $145 million.